Development and assessment of a clinical calculator for estimating the likelihood of recurrence and survival among patients with locally advanced rectal cancer treated with chemotherapy, radiotherapy, and surgery by Weiser, Martin R et al.
© 2021 Weiser MR et al. JAMA Network Open. 
Supplementary Online Content 
 
Weiser MR, Chou JF, Keshinro A, et al; Colorectal Cancer Disease Management Team of 
Memorial Sloan Kettering Cancer Center. Development and assessment of a clinical calculator 
for estimating the likelihood of recurrence and survival among patients with locally advanced 
rectal cancer treated with chemotherapy, radiotherapy, and surgery. JAMA Netw Open. 
2021;4(11):e2133457. doi:10.1001/jamanetworkopen.2021.33457 
 
eMethods. Treatment Regimens 
eTable. Parameter Estimates for Cox Regression Models Predicting RFS and OS 
eFigure. Predictive Equations for Incomplete Responders for RFS and OS 
 
This supplementary material has been provided by the authors to give readers additional 
information about their work. 
© 2021 Weiser MR et al. JAMA Network Open. 
eMethods. Treatment Regimens 
Treatment Regimens  
Chemoradiotherapy consisted of 25 to 28 radiotherapy fractions with concurrent infusional fluorouracil 
at 225 mg/m2 or oral capecitabine at 825 mg/m2 twice daily on days of radiation. The radiotherapy was 
in the form of three-dimensional conformal radiotherapy or intensity-modulated radiotherapy, for a 
total dose of 45 Gy in 1.8-Gy fractions to the pelvis, with a 5.4-Gy boost to the tumor. In three-
dimensional conformal radiotherapy, the boost involved three additional 1.8-Gy fractions (for a total 
dose of 50.4 Gy in 28 fractions), whereas in intensity-modulated radiotherapy the boost involved dose 
painting to 2.0 Gy/fraction (for a total dose of 50 Gy in 25 fractions). Adjuvant therapy, generally 
mFOLFOX for eight cycles or CAPOX for five cycles, was delivered in accordance with the national 
guidelines (www.nccn.org). Prior to 2004, adjuvant therapy consisted of fluorouracil and leucovorin.  
Short-course radiotherapy consisted of 25 Gy of three-dimensional conformal radiotherapy delivered 
over 5 days and was followed by 4 months of modified FOLFOX or CAPOX and then total mesorectal 
excision.  
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eTable. Parameter Estimates for Cox Regression Models Predicting RFS and OS 
 
RFS 
Variable HR (95%CI) 
ypT0/T1 Ref 
ypT2 vs ypT0/T1 1.37 (0.67-2.79) 
ypT3 vs ypT0/T1 1.94 (0.97-3.86) 
ypT4 vs ypT0/T1 4.58 (1.70-12.4) 
Positive LN NDI 
DTAV >=5 vs <5 0.68 (0.49-0.94) 
LVI Yes vs No 1.15 (0.77-1.69) 
PNI Yes vs No 1.88 (1.32-2.70) 
 
OS 
Variable HR (95%CI) 
Age NDI* 
ypT3 vs ypT0/T1/T2 1.48 (1.07-2.04) 
ypT4 vs ypT0/T1/T2 3.80 (1.72-8.41) 
Positive LN NDI 
DTAV >=5 vs <5 0.69 (0.50-0.96) 
LVI Yes vs No 1.09 (0.73-1.62) 
PNI Yes vs No 2.02 (1.41-2.91) 
 
DTAV, distance of tumor to anal verge; HR, hazard ratio; LN, lymph node; venous invasion, large and small 
vessel lymphovascular invasion; OS, overall survival; PNI, perineural invasion; RFS, relapse-free survival; 
T, pathologic T category; ypT, pathologic AJCC tumor classification  NDI, no direct interpretation of HRs 
because the continuous variable was modeled using restricted cubic splines 
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eFigure. Predictive Equations for Incomplete Responders for RFS (top) and OS (bottom) 
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